Shown verbatim: the complete text as captured from the official PDF posted by the Oklahoma Legislature, fetched 2026-07-23. Page and line markers are part of the official record; nothing is edited or removed. The official bill page.
1 STATE OF OKLAHOMA
1
2 1st Session of the 60th Legislature (2025)
2
3 SENATE BILL 574 By: Haste
3
4
4
5
5
6 AS INTRODUCED
6
7 An Act relating to the Attorney General; amending 74
7 O.S. 2021, Section 30.5, as last amended by Section
8 3, Chapter 124, O.S.L. 2024 (74 O.S. Supp. 2024,
8 Section 30.5), which relates to definitions used in
9 the Political Subdivisions Opioid Abatement Grants
9 Act; modifying definitions; removing obsolete
10 language; amending 74 O.S. 2021, Section 30.6, which
10 relates to the Oklahoma Opioid Abatement Revolving
11 Fund; authorizing the Office of the Attorney General
11 to use certain funds for specified purpose; updating
12 statutory reference; amending 74 O.S. 2021, Section
12 30.8, as amended by Section 2, Chapter 75, O.S.L.
13 2022 (74 O.S. Supp. 2024, Section 30.8), which
13 relates to disbursement of grants; broadening
14 applicability of certain provisions; updating
14 statutory language; and providing an effective date.
15
15
16
16
17 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
17
18 SECTION 1. AMENDATORY 74 O.S. 2021, Section 30.5, as
18
19 last amended by Section 3, Chapter 124, O.S.L. 2024 (74 O.S. Supp.
19
20 2024, Section 30.5), is amended to read as follows:
20
21 Section 30.5. As used in the Political Subdivisions Opioid
21
22 Abatement Grants Act:
22
23 1. "Approved purpose" and "approved purposes" mean evidence-
23
24 based, forward-looking strategies, programming and services used to:
24
Req. No. 472 Page 1
1 a. expand the availability of treatment for individuals
1
2 affected by opioid use disorders, co-occurring
2
3 substance use disorders and mental health issues,
3
4 b. develop, promote and provide evidence-based opioid use
4
5 prevention strategies,
5
6 c. provide opioid use disorder and co-occurring substance
6
7 use disorder avoidance and awareness education,
7
8 d. decrease the oversupply of licit and illicit opioids,
8
9 e. support recovery from addiction services performed by
9
10 qualified and appropriately licensed providers,
10
11 f. treat opioid use, abuse and disorders including early
11
12 intervention screening, counseling and support,
12
13 g. support individuals in treatment and recovery from
13
14 opioid use, abuse and disorder,
14
15 h. provide programs or services to connect individuals
15
16 with opioid use, abuse or disorder, or who are at risk
16
17 of developing opioid use disorder, co-occurring
17
18 substance use disorder and mental health issues, with
18
19 treatment and counseling programs and services,
19
20 i. address the needs of individuals who are involved, or
20
21 who are at risk of becoming involved, in the criminal
21
22 justice system due to opioid use, abuse or disorder
22
23 through programs or services in municipal and county
23
24 criminal judicial systems including prearrest and
24
Req. No. 472 Page 2
1 postarrest diversion programs, pretrial services and
1
2 drug or recovery courts,
2
3 j. address the needs of pregnant or parenting women with
3
4 opioid use, abuse or disorder and their families,
4
5 k. address the needs of parents and caregivers caring for
5
6 babies with neonatal abstinence syndrome,
6
7 l. support efforts to prevent overprescribing and ensure
7
8 appropriate prescribing and dispensing of opioids,
8
9 m. support efforts to discourage or prevent misuse of
9
10 opioids including the oversupply of licit and illicit
10
11 opioids,
11
12 n. support efforts to prevent or reduce overdose deaths
12
13 or other opioid-related harms including through
13
14 increased availability and distribution of naloxone
14
15 and other drugs that treat overdoses for use by first
15
16 responders, persons who have experienced an overdose
16
17 event, families, schools, community-based service
17
18 providers, social workers and other members of the
18
19 public,
19
20 o. reimburse or fund law enforcement and emergency
20
21 responder expenditures relating to the opioid epidemic
21
22 including costs of responding to emergency medical or
22
23 police calls for service, equipment, treatment or
23
24 response alternatives, mental health response training
24
Req. No. 472 Page 3
1 and training for law enforcement and emergency
1
2 responders as to appropriate practices and precautions
2
3 when dealing with opioids or individuals who are at
3
4 risk of opioid overdose or death,
4
5 p. reimburse attorney fees and allowable expenses
5
6 directly related to opioid litigation incurred as part
6
7 of legal services agreements entered into before May
7
8 21, 2020,
8
9 q. support efforts to provide leadership, planning and
9
10 coordination to abate the opioid epidemic through
10
11 activities, programs or strategies for prevention and
11
12 recovery models including regional intergovernmental
12
13 efforts and not-for-profit agency support,
13
14 r. support education of youths regarding the dangers of
14
15 opioid use, abuse and addiction,
15
16 s. fund training relative to any approved purpose,
16
17 t. monitor, surveil and evaluate opioid use, abuse or
17
18 disorder,
18
19 u. provide educational and health care services related
19
20 to nonopioid treatment alternatives, or
20
21 v. provide opioid abatement as identified by the Oklahoma
21
22 Opioid Abatement Board as consistent with the purpose
22
23 of the Political Subdivisions Opioid Abatement Grants
23
24 Act.
24
Req. No. 472 Page 4
1 Provided that, such strategies, programming and services occurred on
1
2 or after January 1, 2015.
2
3 Approved purpose also includes any approved uses as authorized
3
4 by opioid-related settlement agreements in which the State of
4
5 Oklahoma is a litigant or participant;
5
6 2. "Board" means the Oklahoma Opioid Abatement Board;
6
7 3. "Eligible participant" means any political subdivision
7
8 impacted by the opioid crisis;
8
9 4. "Nonapproved purpose" and "nonapproved purposes" mean
9
10 strategies, programming and services not falling within the
10
11 definition of approved purpose or approved purposes as defined in
11
12 this section;
12
13 5. "Opioid funds" means all monetary amounts obtained through a
13
14 settlement or judgment by the Attorney General on behalf of this
14
15 state related to opioid litigation involving pharmaceutical supply
15
16 chain participants including the Purdue Political Subdivisions
16
17 Subdivision Fund but excluding all other funds received pursuant to
17
18 the Purdue Settlement Agreement;
18
19 6. "Opioid grant awards" means grants funded from the Oklahoma
19
20 Opioid Abatement Revolving Fund, awarded pursuant to the provisions
20
21 of the Political Subdivisions Opioid Abatement Grants Act;
21
22 7. "Pharmaceutical supply chain" means the process and channels
22
23 through which controlled substances are manufactured, marketed,
23
24 promoted, distributed or dispensed;
24
Req. No. 472 Page 5
1 8. "Pharmaceutical supply chain participant" means any entity
1
2 that engages in or has engaged in the manufacture, marketing,
2
3 promotion, distribution or dispensing of an opioid analgesic;
3
4 9. "Political subdivision" and "political subdivisions" have
4
5 the same meaning as provided in subparagraphs a, b, c and d of
5
6 paragraph 11 of Section 152 of Title 51 of the Oklahoma Statutes.
6
7 Political subdivision also means the board of regents or board of
7
8 trustees of a state educational institution which is a member of The
8
9 Oklahoma State System of Higher Education;
9
10 10. "Purdue Political Subdivision Fund" means the Twelve
10
11 Million Five Hundred Thousand Dollars ($12,500,000.00) plus any
11
12 interest accrued thereon received from the Revive Oklahoma Health
12
13 Foundation consisting of funds received from the Purdue Settlement
13
14 Agreement designed for distribution to political subdivisions which
14
15 have executed a release of legal claims as required by the Purdue
15
16 Settlement Agreement; and
16
17 11. "Purdue Settlement Agreement" means the settlement
17
18 agreement entered into by this state and Purdue Pharma L.P., Purdue
18
19 Pharma, Inc. and the Purdue Frederick Company on March 26, 2019, and
19
20 approved by the Court on April 2, 2019.
20
21 SECTION 2. AMENDATORY 74 O.S. 2021, Section 30.6, is
21
22 amended to read as follows:
22
23 Section 30.6. A. There is hereby created in the State Treasury
23
24 a revolving fund for the Office of the Attorney General to be
24
Req. No. 472 Page 6
1 designated the "Oklahoma Opioid Abatement Revolving Fund". The fund
1
2 shall be a continuing fund, not subject to fiscal year limitations,
2
3 and shall consist of all opioid funds obtained through a settlement
3
4 or judgment by the Attorney General on behalf of the State of
4
5 Oklahoma related to opioid litigation involving pharmaceutical
5
6 supply chain participants:
6
7 1. Designated for deposit in the fund; or
7
8 2. Appropriated to the fund by the Legislature.
8
9 B. Provided that the Purdue Political Subdivisions Subdivision
9
10 Fund shall be maintained in a segregated State Treasury fund within
10
11 the Oklahoma Opioid Abatement Revolving Fund, and that the Purdue
11
12 Political Subdivisions Subdivision Fund shall not be commingled with
12
13 other opioid funds deposited in or appropriated to the Oklahoma
13
14 Opioid Abatement Revolving Fund.
14
15 C. The Office of the Attorney General may use not more than ten
15
16 percent (10%) of the funds appropriated to the Oklahoma Opioid
16
17 Abatement Revolving Fund for statewide opioid abatement projects
17
18 that constitute an approved use under the Political Subdivisions
18
19 Opioid Abatement Grants Act.
19
20 D. All monies accruing to the credit of the fund are hereby
20
21 appropriated and may be budgeted and expended by the Attorney
21
22 General for the purpose of funding opioid grant awards as authorized
22
23 by this act the Political Subdivisions Opioid Abatement Grants Act.
23
24
24
Req. No. 472 Page 7
1 SECTION 3. AMENDATORY 74 O.S. 2021, Section 30.8, as
1
2 amended by Section 2, Chapter 75, O.S.L. 2022 (74 O.S. Supp. 2024,
2
3 Section 30.8), is amended to read as follows:
3
4 Section 30.8. A. 1. The Oklahoma Opioid Abatement Board shall
4
5 conduct an initial disbursement one or more disbursements of opioid
5
6 grant awards to participating eligible participants. Such opioid
6
7 grant awards shall be allocated amongst the different participating
7
8 eligible participants based on the following criteria:
8
9 a. the number of people per capita suffering from opioid
9
10 use disorder in the participating political
10
11 subdivision, or in the absence of such information,
11
12 the opioid prescription rate in the political
12
13 subdivision compared to the national average opioid
13
14 prescription rate,
14
15 b. the number of opioid overdose deaths in the
15
16 participating political subdivision,
16
17 c. the amount of opioids distributed within the
17
18 participating political subdivision, and
18
19 d. the amount of attorney fees and allowable expenses
19
20 associated with legal services agreements directly
20
21 related to opioid litigation incurred as part of legal
21
22 services agreements entered into before May 21, 2020,
22
23 or
23
24 e. any other criteria established by the Board.
24
Req. No. 472 Page 8
1 2. Grant awards shall be subject to legal services agreements
1
2 entered into by eligible participants.
2
3 3. Initial opioid Opioid grant awards as provided for in this
3
4 subsection shall be listed in an opioid grant award distribution
4
5 table reviewed and approved by the Board to ensure that such awards
5
6 adhere to the criteria adopted by the Board.
6
7 B. Following the awarding of opioid grant awards pursuant to
7
8 subsection A of this section, any remaining unencumbered balance in
8
9 Funds accrued in the Oklahoma Opioid Abatement Revolving Fund shall
9
10 be available to the Board to award as grants to eligible
10
11 participants; provided such awards shall only be utilized by
11
12 eligible participants for approved purposes.
12
13 C. In the event an eligible participant merges, dissolves or
13
14 ceases to exist, any remaining allocations of an awarded opioid
14
15 grant award in excess of Five Hundred Dollars ($500.00) shall be
15
16 reallocated equitably based on the composition of the successor
16
17 eligible participant or the successor eligible participants.
17
18 SECTION 4. This act shall become effective November 1, 2025.
18
19
19
20 60-1-472 DC 1/19/2025 5:39:01 AM
20
21
21
22
22
23
23
24
24
Req. No. 472 Page 9Every fact on this page links to its source, starting with the official bill record.